Physician profile
Scott C Grevey
NPI 1699713107
$583.04
in general payments reported to CMS, 2019-2025
10 companies · $67.75 in 2025
The $67.75 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.49 · 2020: $42.33 · 2021: $48.70 · 2022: $39.92 · 2023: $301 · 2024: $15.17 · 2025: $67.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $368 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.33 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $235.98 | 2020-2023 | Tremfya, Stelara, Remicade |
| Organogenesis INC. | $72.99 | 2021-2025 | Via Matrix |
| Amgen INC. | $49.18 | 2020-2023 | Otezla |
| Pfizer INC. | $43.96 | 2023 | |
| Sientra, INC. | $43.13 | 2019 | |
| Allergan, INC. | $36.84 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $34.87 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $33.10 | 2023-2024 | Sotyktu |
| Genentech USA, INC. | $16.79 | 2023 | Erivedge |
| Abbvie INC. | $16.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Grevey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.